Why does the loss occur at all?
Dispensing at a loss is frequently experienced as a purchasing failure, as though a better buyer would have avoided it. The structure indicates otherwise, and understanding the structure is what converts the experience from a source of frustration into a manageable operational variable.
National community pharmacy funding in England comprises two elements. Remuneration consists of the fees and allowances paid for services performed. Retained margin consists of the difference between what a pharmacy pays for a medicine and what it is reimbursed, which pharmacies are permitted to keep as part of the agreed funding. For 2026/27 the core contractual framework provides £3.636 billion, of which £1.1 billion is intended for delivery as retained buying margin, that figure having been increased by £200 million as part of the settlement.
The consequence is that a material portion of the sector's income is not paid but earned, through purchasing medicines below the reimbursement price. The Department delivers the margin target principally by adjusting reimbursement prices within Category M of the Drug Tariff, setting them above the prices notified by manufacturers so that the difference accrues to contractors.
That mechanism works whilst the market behaves as the model assumes. Where a product's actual market price rises above its Tariff price, whether through shortage, manufacturer withdrawal, raw material cost or exchange rate movement, the arithmetic inverts and every item dispensed produces a loss rather than a margin. The pharmacy has not purchased badly. The reimbursement price has been overtaken by the market it was set against.
How is reimbursement set?
Part VIII of the Drug Tariff establishes reimbursement prices for generic medicines, and its categories operate differently in ways which determine how quickly each responds to market movement.
| Category | What it covers | How the price behaves |
|---|---|---|
| Part VIIIA Category A | Products readily available, priced from a basket of supplier list prices | Moves with the sources it is drawn from, and may lag a rapid market change |
| Part VIIIA Category C | Products not readily available as generics, priced from a named source | Follows the nominated source rather than the wider market |
| Part VIIIA Category M | Products where the price is set to deliver the margin target | Adjusted periodically by the Department, deliberately above notified manufacturer prices |
| Parts VIIIB and VIIID | Specials and unlicensed imports, and certain other listed products | Concessions may also be requested here where sourcing above Tariff occurs |
Two features of that arrangement produce the recurring difficulty. Category M prices are set to achieve a national margin figure rather than to track any individual product's market, which means an individual line may be priced below its own market whilst the aggregate remains on target. And every category is set periodically rather than continuously, whilst supply markets move daily, so that a gap opens whenever a market moves faster than the review cycle.
A further consequence deserves noting, since it affects pharmacies unequally. Because margin is delivered through prices which some pharmacies capture better than others, according to purchasing arrangements, volumes and product mix, the distribution of that funding across the sector is uneven, which is a recognised limitation of the mechanism rather than a criticism of any particular pharmacy's buying.
What is a concession, and what is it not?
Where pharmacies cannot obtain a Part VIII product at or below its Tariff price, the Department of Health and Social Care may grant a price concession at the request of Community Pharmacy England, raising the reimbursement price for that month. Contractors dispensing the affected product are then reimbursed at the revised price automatically, and no additional endorsement is required.
Three characteristics warrant stating precisely, since each is regularly misunderstood.
A concession is monthly. It applies for the month in which it is granted rather than continuing until withdrawn, which means a product conceded in one month reverts to its Tariff price in the next unless conceded again. Prices agreed for concessions requested late within a month roll over into the following month, and rolled-over prices may be adjusted upward where reports indicate suppliers' prices have risen further, with a review available at any point during the month.
A concession is a reimbursement price rather than a reimbursement of loss. It sets what will be paid for items dispensed within that month, and does not compensate for the difference between what was paid for stock and what was received before the concession existed. Where purchasing and dispensing fall either side of a concession's timing, the shortfall is genuine.
A concession is applied for rather than triggered. No system detects that a market has moved. Community Pharmacy England applies on the basis of evidence submitted by contractors, and the Department decides. That dependency is the subject of the section below, and is the element of the whole mechanism which a pharmacy owner directly controls.
How does the monthly cycle operate?
Concessions are not published as a single monthly list but confirmed in tranches as applications are determined, which produces a rhythm worth anticipating rather than reacting to.
July 2026 illustrates the pattern. An initial list was confirmed mid-month, with further lists following on subsequent dates, and by the confirmation of 22 July the total granted for the month had reached 183, with applications for additional products still outstanding at that point. June 2026 concluded at 254 concessions granted. Community Pharmacy England publishes a dashboard tracking the monthly totals over time and by Drug Tariff category, which is the appropriate source for anyone assessing whether a given month is unusual.
The operational consequence of tranching is a timing gap which affects every pharmacy the same way. Stock is purchased throughout the month, whilst concessions for that month may not be confirmed until its final week. A pharmacy therefore purchases in uncertainty and is reimbursed in retrospect, and the interval between the two is where the discomfort sits. Nothing within the pharmacy's control removes that gap, though the purchasing habits described below reduce its cost.
Why does reporting decide the outcome?
No mechanism detects that a product has become unobtainable at Tariff price. Community Pharmacy England learns of it because dispensing contractors report what they paid and to whom, and applications to the Department are constructed from that evidence. The reporting route asks for the product, the supplier and the price paid, which is precisely the information sitting within a purchase invoice and nowhere else. The consequence is that a pharmacy absorbing a loss silently has not merely accepted a cost but withheld the evidence upon which the correction depends, for itself and for every other pharmacy dispensing the same product. Reporting takes minutes, applies to a system which reimburses automatically once the concession is granted, and constitutes the only part of this mechanism which an individual owner influences directly. It warrants treating as a standing operational task rather than as an occasional grievance.
Two practical points improve the quality of what is submitted. Report with the invoice rather than from recollection, since the application requires supplier and price and an approximate figure weakens the evidence. And report promptly, since a concession requested late in a month rolls into the next, whilst one requested early may be determined within the month in which the loss is being incurred.
What do concessions not fix?
The mechanism is a correction rather than a solution, and four limitations warrant understanding by anyone planning around it.
The timing gap. Purchases precede concessions, and the interval is not compensated.
The threshold effect. A concession is granted where the evidence supports it, which means losses on products with limited dispensing volume, or where reporting is thin, may persist uncorrected simply because the evidence never accumulated.
The distribution question. Because margin is delivered through purchasing, and purchasing capability varies with scale and arrangements, the funding does not reach every pharmacy equally even when the national total is delivered.
The structural point. Concessions correct the symptom of a funding model which delivers a substantial proportion of income through the difference between two prices, one of which is set administratively and the other by a market. The volume of concessions being granted is therefore a measure of how frequently that model requires correction, which is why the sector's representative body publishes the trend rather than merely the monthly list.
What is the operational response?
Four habits reduce the cost of the mechanism without pretending to remove it.
Purchase with the cycle in mind. Where a product is known to be under pressure, buying to need rather than to stock reduces exposure to the interval between purchase and concession, whilst recognising that shortage conditions frequently make the opposite necessary and that clinical continuity outranks margin in that judgement.
Reconcile rather than assume. Reimbursement should be checked against expectation for the products where the amounts are material, since payment and pricing accuracy is itself a recognised issue and a concession granted is not the same as a concession correctly applied to a particular month's dispensing.
Report as routine. A standing weekly task, assigned to a named person, converts reporting from something which happens when someone is sufficiently annoyed into something which happens whenever an invoice exceeds Tariff.
Watch the announcements deliberately. Since concessions arrive in tranches, a pharmacy checking once a month at the wrong moment sees an incomplete picture, and the dashboard and update notices are more useful read on a schedule than encountered incidentally.
What is the 2026/27 position?
The concessions mechanism sits within a funding settlement which improved materially for 2026/27 whilst leaving the underlying structure intact. Core contractual framework funding rose by 10.3 per cent to £3.636 billion, which represented the highest uplift across primary care for that year, and the retained medicine margin increased by £200 million to £1.1 billion. The Government additionally agreed to write off historic net margin over-delivery earned to the end of March 2026, which Community Pharmacy England indicated saved pharmacy owners a sum of up to £239 million in recovery. The Single Activity Fee increased, and Independent Prescribing within Pharmacy First and the Pharmacy Contraception Service were scheduled for introduction during the year.
Two observations follow for an owner reading this alongside their own accounts. The settlement was accepted upon the condition of a shared programme of reform rather than as a resolution, and the sector's representative body was explicit that the uplift addressed the position without altering the model. And the margin element, having increased, remains an amount to be earned through purchasing rather than an amount to be received, which means the concessions mechanism, and the reporting upon which it depends, matters more rather than less as the figure rises.
For context concerning the volumes involved, the Department recorded that community pharmacies dispensed around one billion prescription items between April 2025 and January 2026, alongside over 2.75 million Pharmacy First clinical pathways consultations, nearly one million contraception service consultations and three million hypertension case-finding consultations within the same ten months.
A note on the devolved nations
The mechanism described here operates in England, where Community Pharmacy England negotiates with the Department of Health and Social Care and concessions apply to the English Drug Tariff. Scotland, Wales and Northern Ireland operate their own reimbursement arrangements and their own routes for addressing products which cannot be obtained at reimbursement price, and the terminology, timing and evidence requirements differ accordingly. Operators working across borders should treat the arrangements as separate rather than analogous, and should consult the relevant national body rather than reasoning from the English position.
Key takeaways
- Dispensing at a loss is structural rather than a purchasing failure, since a substantial portion of English community pharmacy income is delivered as retained buying margin, set at £1.1 billion for 2026/27 within a £3.636 billion framework.
- Category M prices are set to deliver a national margin target rather than to track individual products, and every Tariff category is reviewed periodically whilst markets move daily, which is where the gap originates.
- A concession raises the reimbursement price for the month it is granted, requires no additional endorsement, and applies automatically, whilst rolling over where agreed late and remaining open to upward review.
- Concessions arrive in tranches rather than as one list, with 254 granted for June 2026 and 183 for July 2026 as at 22 July, and the trend is published as a dashboard by Drug Tariff category.
- The mechanism is evidence-led, in that concessions are applied for using supplier and price data which only dispensing contractors hold, such that absorbing a loss silently withholds the evidence upon which the correction depends.
- Concessions do not compensate for the timing gap, do not reach products where evidence never accumulates, and do not resolve the uneven distribution which delivering funding through purchasing produces.
- The operational response comprises purchasing with the cycle in mind, reconciling reimbursement rather than assuming it, reporting as a standing weekly task, and reading the announcements on a schedule.
FAQs
Margin earned, not assumed.
Reporting above-Tariff purchases requires knowing which lines were bought above Tariff, which is a data question before it is an administrative one. Dataforge PMR holds dispensing and purchase records in one place, and the reconciliation habit this article describes runs upon exactly that. Where the loss is visible only at the quarter end, the records are the constraint rather than the market.
See Dataforge PMR